Tcelltech GmbH, a spin-out of the German Cancer Research Center (DKFZ), develops a universal personalised adoptive cell therapy against all cancers (UNIPACT).
UNIPACT is based on two platform technologies:
(I) a high-performance gene expression DNA vector platform (nanoSMAR)
(II) an AI bioinformatics platform which identifies reactive T cell receptors (selecTCR).